<DOC>
	<DOC>NCT02414516</DOC>
	<brief_summary>This Phase 1a, single center, open-label, repeat dose study will evaluate the safety, efficacy, and Pharmacokinetics of ascending doses of OBP-801 in patients with advanced solid tumors.</brief_summary>
	<brief_title>A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Patient Inclusion Criteria Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study: Histologically or cytologically confirmed metastatic or unresectable solid tumor. Has failed treatment with all standard therapies for their malignancy. Adequate Karnofsky Performance Status. An expected survival of at least 3 months. Adequate organ and bone marrow function. Signed informed consent form for study participation prior to screening. Patient Exclusion Criteria Patients presenting with any of the following will be excluded in the study: Clinically significant disease as defined by the protocol. Surgical therapy or other therapies within period as defined by the protocol. Any condition that will interfere with compliance with the protocol as determined by investigator.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>HDAC</keyword>
	<keyword>Epigenetic</keyword>
	<keyword>Histone</keyword>
	<keyword>Acetylation</keyword>
</DOC>